Regeneron Pharmaceuticals REGN

Healthcare · Biotechnology · Synthos Deep Dive · 2026-07-03

$654.27

Watch

Risk 4Growth 6Exponential 4Fair value $785 $490–$1010

—

At a glance

Verdict	Watch — systematic Synthos tier
Price (2026-07-02)	$654.27 · market cap ~$67.4B
Synthos scores (0–10)	Downside Risk 4 · Growth Quality 6 · Exponential Potential 4
Synthos fair value (base case)	~$785 → +20% · full range $490 (bear) – $1,010 (bull)
Street consensus	$836 (high $995 / low $641; 32 Buy · 16 Hold · 0 Sell) — context, not our anchor
Valuation	15× trailing EPS · 14× FY26E · 12× FY27E · 9× FY30E · EV/S 4.5× · EV/EBITDA 11.7×
Exponential Potential	4/10 · Low-Moderate — ~11% forward EPS CAGR, Dupixent + pipeline optionality, but a mature large-cap past its steepest growth
Technicals	Downtrend — $654, −19% off 52-wk high, below 50/200-DMA, RSI 76 (overbought bounce), +22% 12-mo
Conviction	Low — only 1 net-bullish voice / 10 claims in the KB (all management-sourced); the call rests on quant + fundamentals
Position sizing	Satellite, ~1–3% — a value/optionality position, not a core holding
Next catalyst	2026-07-30 Q2'26 earnings (Street EPS $10.81)
Single biggest risk	Eylea (branded + HD) erosion from biosimilars and Vabysmo — the legacy cash engine is in structural decline

One-line thesis. Regeneron is a rare cheap large-cap biotech — 15× trailing earnings, net cash, 84% gross margin — where the market has repriced the stock for a shrinking Eylea franchise (−46% peak-to-trough), while Dupixent (a Sanofi-shared blockbuster still growing double digits) and a broad late-stage pipeline provide the growth and optionality; we see modest upside to a ~$785 base case, but the thin expert coverage and franchise erosion keep this a tactical, not a core.

◆ Synthos call — Watch REGN is a business we want at a price we don't have — it becomes a Buy below ~$700; until then, do nothing.

Downside Risk (lower = safer)

4/10 · Moderate

Net-cash fortress balance sheet, 0.24 beta, 15× trailing — but Eylea erosion & a −46% drawdown show real franchise risk.

Growth Quality

6/10 · High

~11% forward EPS CAGR, 84% gross margin, but flat FY25 revenue and Eylea decline cap the quality score.

Exponential Potential

4/10 · Moderate

Dupixent + pipeline (Lynozyfic, factor XI, oncology) give optionality, but a mature $67B name growing high-single-digits is no multibagger.

⚖ Reverse-DCF cross-check Market-implied growth ≈ 6%/yr To justify today’s $654, earnings would have to compound roughly 6% a year for 10 years (9% discount rate). Analysts forecast ~9%/yr, so the market is pricing in LESS than what the Street expects.

What do the 5 tiers mean? (Core · Tactical · Watch · Hold · Avoid)

Buy — CoreOwn it as a foundation — start or add now, size it for years, let dips be gifts.

Buy — TacticalGood price + confirmed trend + a defined exit — buy the setup, not a marriage.

WatchWe want the business, just not at this price/setup — act only when the listed trigger hits.

HoldFine to keep if you own it — no reason to buy more; new money does better elsewhere.

AvoidDon't own it — the problem is the business or the expectations, so a cheaper price won't fix it.

In plain English

Regeneron is a big biotech company. Its two money-makers are Eylea, an eye injection for macular degeneration, and Dupixent, an injection for eczema and asthma that it splits with partner Sanofi. Dupixent is still growing fast; Eylea is shrinking because cheaper copycats and a rival drug (Vabysmo) are stealing its market. That is why the stock has fallen hard — down about 20% from its recent high and nearly cut in half from its all-time peak.

Here is the interesting part: after that fall, the stock is now cheap for a company this profitable — you pay about $15 for every $1 of annual profit (the average big company is closer to $20–25), and Regeneron has more cash than debt. Our verdict is Buy as a smaller "satellite" position — a value-and-optionality bet, not a core holding, because the shrinking Eylea business is a real worry and almost no expert analysts we track cover this name.

Here's what our three scores mean in everyday terms:

Downside Risk 4/10 (fairly safe on the numbers). Loads of cash, almost no debt, a very steady (low-beta) stock and a cheap price — but the business itself is losing ground, and the stock has already had a big drop.
Growth Quality 6/10 (decent, not great). Extremely profitable and Dupixent grows well, but total sales were basically flat last year because Eylea is fading.
Exponential Potential 4/10 (low-to-moderate). Some real upside from new drugs, but this is already a mature $67 billion company — don't expect it to double quickly.

The one big worry: Eylea — the older cash-cow drug — is in structural decline. The whole "cheap stock" case only works if Dupixent and the new pipeline drugs grow enough to offset it.

Price & moving averages 12 months · 50 & 200-day averages · 52-week range

Solid = price · dashed = 50-day average · dotted = 200-day average · amber = 52-week high/low. Price above both averages is an uptrend.

Bollinger Bands 20-day average ± 2 standard deviations

The shaded band widens when the stock gets more volatile. Riding the upper edge = strong momentum (sometimes stretched); the lower edge = weak / potentially oversold.

RSI (14) momentum gauge · 0–100

Above 70 (red band) = overbought, below 30 (green band) = oversold. Currently 60.

MACD 12 / 26 / 9 · trend & momentum

Blue crossing above amber (bars flip green) = momentum turning up; below (bars red) = turning down. Bar height = the size of that gap.

Relative performance vs S&P 500 & its sector (XLV (sector)), set to 100 a year ago

Solid = REGN · dashed = S&P 500 · dotted = XLV (sector). A rising line means it is beating that benchmark — the sector line shows whether it is a leader or laggard within its own group.

Forward revenue & earnings actual → estimate · "FY" = fiscal year, "E" = estimate

Darker bars = actual results, brighter = analyst estimates. Taller bars to the right = expected growth.

Key stats an RIA wants

Price$654.27

Market cap$67B

P/E trailing29×

P/E FY26E / FY27E14× / 12×

EV / Sales4.5×

EV / EBITDA11.7×

Gross margin84.5%

Net margin29.6%

Dividend yield0.56%

Beta0.238

52-wk range$538 – $812

RSI(14)76

50 / 200-DMA$658 / $700

12-mo return+22% (SPY +21%)

Street target$836 ($641–$995)

Analyst grades32 Buy · 16 Hold · 0 Sell

FMP ratingA

Next earnings2026-08-05

What the experts actually said 10 traceable claims on REGN · showing the highest-conviction voices

“Board authorized a new $3.0 billion share repurchase program with no time limit, plus a $0.94 per share dividend.”

Regn Mgmtmanagementconviction 702026-04-29REGN-earnings-2026Q2:3804e10c8e

“GAAP gross margin will remain negatively impacted by Limerick production interruption until output returns to normal, expected by end of Q2 2026.”

Regn Mgmtmanagementconviction 702026-04-29REGN-earnings-2026Q2:1463389f1e

Every claim reconciles to a real claim_id in the Synthos knowledge base — this is the evidence the verdict is built on, not vibes. Management (the company itself) is shown but half-weighted; one cautionary voice is included on purpose.

1. What it is

Regeneron Pharmaceuticals (NASDAQ: REGN) is a Tarrytown, NY biotechnology company founded in 1988, built on its proprietary antibody-discovery platforms (VelocImmune / VelociSuite). Its economics rest on two pillars:

Eylea / Eylea HD (aflibercept) — anti-VEGF eye injections for wet AMD, diabetic macular edema and related retinal diseases. This is the legacy cash engine, now under pressure from biosimilars and Roche's Vabysmo; the higher-dose Eylea HD is Regeneron's defense.
Dupixent (dupilumab) — a blockbuster anti-inflammatory (atopic dermatitis, asthma, COPD, and expanding indications), co-developed and shared with Sanofi. Dupixent global sales run well above Regeneron's own reported revenue because Sanofi books the sales and Regeneron recognizes its share largely through collaboration revenue.

Other marketed drugs: Libtayo (oncology, PD-1), Praluent (cholesterol), Kevzara, ARCALYST, plus a late-stage pipeline spanning oncology (bispecifics like linvoseltamab/Lynozyfic), hematology, factor XI (cardiovascular), and genetic-medicine collaborations (Alnylam, Intellia). Fiscal year ends December 31.

Revenue mix (FY2025, from filings):

By type: Collaboration revenue $7.33B (largely the Sanofi/Bayer share — this is where Dupixent economics show up) · Product $6.31B (Eylea, Libtayo, etc.) · Other $0.70B. Total FY25 revenue $14.34B. The heavy collaboration weighting is the single most important structural feature: a large slice of Regeneron's value flows through partnerships, not its own product P&L.
By geography (product-level segmentation, FMP): United States $4.38B (90%) · Rest of World $0.51B. Regeneron's own product revenue is overwhelmingly US; ex-US Dupixent/Eylea economics sit with Sanofi/Bayer. This is both a US-pricing-policy exposure and a concentration flag (§11).

2. The expert thesis — (thin coverage; fundamentals-driven)

Honest disclosure: Regeneron has essentially no independent expert coverage in the Synthos knowledge base. The KB holds 10 total claims and exactly one net-bullish "voice," and that voice is Regeneron's own management (REGN_mgmt, a half-weighted, talks-its-own-book source). There is no high-skill outside analyst (no Visser, no Invest-Like-the-Best-style thesis) on this name. Accordingly, this verdict is quant- and fundamentals-driven, not conviction-driven — and it is sized as a tactical position precisely because the breadth is absent.

What the two dated, traceable management claims tell us (both 2026-04-29, Q1'26 call):

Capital return (bullish signal). Management (REGN-earnings-2026Q2:3804e10c8e, conviction 70) disclosed the board authorized a new $3.0B share-repurchase program with no time limit, plus a $0.94/share quarterly dividend. On a $67B cap that buyback is ~4.5% of shares — meaningful, and consistent with the FY25 cash-flow statement ($3.97B of stock repurchased, $0.37B dividends).
Manufacturing headwind (bearish signal, self-flagged). Management (REGN-earnings-2026Q2:1463389f1e, conviction 70) warned that GAAP gross margin will remain hit by a Limerick production interruption until output normalizes, expected end of Q2 2026. This is a real near-term margin drag and partly explains the soft FY25 revenue print — but it is management's stated view that it is transient.

Composite note. With a single half-weighted source, we assign zero net expert conviction and lean entirely on the quant/fundamental picture below. If an outside high-skill voice initiates coverage, the conviction rating can rise; today it cannot honestly.

3. Synthos scores & the Bull / Base / Bear cases

The one-glance judgment — three scores, 0–10, each anchored to real metrics (not probabilities we can't honestly calibrate):

Score	0–10	The read
Downside Risk (lower = safer)	4 · Moderate-Low	Net cash (net-debt/EBITDA −0.04×), beta 0.24, 15× trailing and 2.2× book give real valuation support — but a −46% max drawdown and the structural Eylea decline are genuine business risk, not just noise.
Growth Quality	6 · Solid	84.5% gross margin, ~30% net margin, ROE 14%; ~11% forward EPS CAGR on estimates — but FY25 revenue was flat (+1%) as Eylea eroded, which caps the quality score below the megacap compounders.
Exponential Potential	4 · Low-Moderate	Dupixent double-digit growth + a broad late-stage pipeline (Lynozyfic, factor XI, oncology bispecifics) is real optionality, but a mature $67B name growing high-single-digit revenue is no multibagger.

The three cases (our own scenario model — assumptions shown; each target is a ~12–18-month fair value). We deliberately do not attach probabilities: the base case is by definition the expected path, so a weighted blend would just restate it with false precision. Instead the cases bound the range, and the scores above summarize them. We anchor on FY27E EPS (the year Eylea HD stabilization and pipeline ramp should be visible).

Case	Key assumptions	Fair value
Bull	Eylea HD defends the retina franchise; Dupixent keeps compounding + new indications; a pipeline win (factor XI or oncology) re-rates the multiple. FY27E EPS beats to ~$60 (vs $54.2 cons); multiple expands to ~17×.	~$1,010 (+54%)
Base (our anchor)	Estimates roughly hit — FY27E EPS ~$54; Eylea decline offset by Dupixent + Libtayo; a net-cash biotech with 84% GM earns a ~14.5× multiple.	~$785 (+20%)
Bear	Eylea erosion accelerates (biosimilars + Vabysmo), Limerick drags longer, pipeline stumbles. FY27E EPS misses to ~$44; multiple de-rates to ~11×.	~$490 (−25%)

Synthos fair value = the base case, ~$785 (+20%), with the full $490–$1,010 span as the honest range. This anchor sits just below the Street's $836 consensus — we give roughly the same credit to FY27 earnings power but discount slightly harder for Eylea structural risk. This is a tracked call — the Forecaster Scorecard grades it once it matures.

4. Exponential Potential

Synthos separates compounders (durable high returns on capital) from exponentials (accelerating, multi-baggers-from-here). REGN is a mature, cash-rich compounder whose steepest growth is behind it:

Forward growth: revenue CAGR FY25→FY30E ~8.4% ($14.3B → $21.5B est); EPS CAGR ~10.6% ($43.48 → $71.92 est) as buybacks and mix help. Solid, not explosive.
Acceleration (the 2nd derivative) is mixed. FY25 revenue was essentially flat (+1%) as Eylea fell; estimates then re-accelerate to +11% FY26E, +11% FY27E, +7% FY28E as Limerick normalizes and Dupixent/pipeline carry the load. So this is a recovery profile off an Eylea-depressed base, not a durable acceleration.
Room to run: the anti-inflammatory (Dupixent) and retinal TAMs are large, and the oncology/factor-XI pipeline adds genuine optionality — but at $67B with high-single-digit top-line, the multibagger math is not there. A 3× from here implies ~$200B, which would require a pipeline blockbuster the market does not yet price.
Reinvestment runway: R&D is a striking 42% of revenue (TTM) — Regeneron out-invests almost every peer in discovery, which is where the real long-run optionality lives, but it also weighs on near-term margins.

Exponential Potential: Low-Moderate (4/10). Own it for a cheap, cash-rich profile with pipeline optionality — not for a fast multibagger. A small accelerating biotech with these margins would score higher; a $67B name past its Eylea peak scores a 4.

5. Financials (real numbers — FMP annual/quarterly)

Revenue: FY25 $14.34B, +1.0% (FY24 $14.20B; FY23 $13.12B). Roughly flat — the Eylea decline offset Dupixent-share growth. Note FY21's $16.1B peak included COVID-antibody (REGEN-COV) revenue that has since rolled off.
Quarterly trajectory: Q1'25 $3.03B → Q2 $3.68B → Q3 $3.75B → Q4 $3.88B → Q1'26 $3.61B (+19% YoY vs Q1'25's depressed base). Sequential softness in Q1'26 partly reflects the Limerick interruption management flagged.
Margins: gross 84.5% TTM, EBITDA margin 38.5%, net 29.6% TTM. Elite gross margin; net margin pressured by the ~42%-of-revenue R&D load.
Earnings: net income $4.50B FY25 (EPS diluted $41.48; basic $43.07), up modestly from $4.41B FY24. Q1'26 net income $0.73B (EPS diluted $6.75) — a soft quarter on the Limerick drag.
Cash flow: operating CF $4.98B FY25, capex −$0.90B, FCF $4.08B (FCF yield ~6.2%). Consistently cash-generative. FY25 returned $3.97B via buybacks + $0.37B dividends.
Balance sheet (fortress): cash & investments $15.7B, total debt $2.7B → net cash ~$0.41B, net-debt/EBITDA −0.04×. Current ratio 3.6×. No solvency risk whatsoever; ~$84/share in cash & short-term investments underpins the floor.

6. Valuation — priced in or room?

Regeneron is genuinely cheap for the quality: 15.4× trailing EPS, 4.5× EV/sales, 11.7× EV/EBITDA, 2.2× book, with a ~6% FCF yield and net cash. On forward estimates the P/E falls to 14× FY26E → 12× FY27E → 9× FY30E — you are paying a below-market multiple for an 84%-gross-margin franchise. The bear's rebuttal is that the cheapness is deserved: Eylea is in structural decline, so trailing earnings may overstate durable earning power, and a chunk of the value depends on the Sanofi-shared Dupixent economics Regeneron doesn't fully control. Our reverse read: at ~$654 the market is pricing roughly flat-to-modest EPS growth and continued Eylea erosion — a low bar that a Dupixent + pipeline offset can clear. Street targets (context): consensus $836, high $995, low $641 — our $785 base FV is marginally below consensus because we discount Eylea harder. A value + optionality buy, not a momentum story.

7. Technicals (computed from EOD price history)

Trend: down. $654 sits below the 50-DMA ($658) and well below the 200-DMA ($700); the 50 is below the 200 (death-cross posture). MACD −4.6 (negative). This is a repair situation, not an established uptrend.
Location: −19.5% off the 52-week high ($812), +21.6% off the 52-week low ($538), with a brutal max drawdown of −45.6% from the multi-year peak — the market has already inflicted heavy pain on the Eylea worry.
Momentum: RSI(14) 76 — overbought (>70). The latest session jumped +4.7%; the print reflects a sharp near-term bounce, so this is not a low-risk technical entry today.
Relative strength: REGN +22.3% 12-mo (vs SPY +20.6%, QQQ +30.3%) — roughly in line with the S&P but lagging the Nasdaq-100. Crucially, 3-mo −15.8% and 6-mo −15.5% while SPY was up — recent relative strength is poor; the 12-mo figure is flattered by an earlier base.
Read: technicals do not confirm the fundamental value case yet — downtrend, death cross, overbought bounce. A value buyer should scale in and prefer pullbacks toward the low-$600s / rising 50-DMA rather than chase the +4.7% pop.

8. Moat & competitive position

Regeneron's moat is its antibody-discovery science (VelociSuite/VelocImmune) — a genuinely productive R&D engine (42% of revenue reinvested) that has generated Eylea, Dupixent, Libtayo and a deep pipeline. The moat is franchise-specific rather than platform-permanent: Eylea faces biosimilars and a differentiated competitor (Roche's Vabysmo), and the Eylea-HD switch is a defensive maneuver, not an expansion. Dupixent's moat is stronger (broad, expanding label; first-mover in multiple type-2 inflammatory indications) but its economics are shared with Sanofi, capping how much accrues to REGN. Net: a high-quality science moat wrapped around a maturing product portfolio.

Peer set (FMP-supplied; note these are healthcare comps, not pure large-cap biotech): argenx $58B, Alnylam $42B, IDEXX $44B, Zoetis $31B, United Therapeutics $24B, Incyte $23B, Genmab $18B, plus managed-care/distribution names (Elevance $91B, Cigna $76B, Cencora $58B) that are not true business comps. Against the biotech comps, REGN's ~15× P/E and net-cash sheet are inexpensive relative to argenx and Alnylam's far richer growth multiples — REGN trades like a value biotech, they like growth biotech.

9. Management, capital allocation & guidance

Leadership: co-founder Leonard Schleifer (CEO) with long-tenured chief scientist George Yancopoulos — a founder-scientist culture that has historically prioritized R&D over financial engineering.
Capital allocation: disciplined and shareholder-friendly at this valuation — a new $3.0B open-ended buyback and a $0.94/quarter dividend (REGN-earnings-2026Q2:3804e10c8e), funded from ~$4B annual FCF and a $15.7B cash pile. Buying back stock at 15× with net cash is rational capital return.
Insider activity: the only sampled Form 4s are tiny director sales (Arthur Ryan, single-digit-share lots around $702–709 in May 2026) — immaterial, routine, no red flag.
Management's own guidance (half-weighted): REGN_mgmt is a skill-0.5 voice (talks its book). Their dated guidance ingested from the SEC 8-K flags the Limerick gross-margin drag normalizing by end-Q2'26 (REGN-earnings-2026Q2:1463389f1e) — a checkable, near-term claim. Gap flagged: full analyst Q&A transcript is not on our FMP plan; we capture prepared guidance today.

10. Catalysts & what to watch

Next earnings: 2026-07-30 (Q2'26; Street EPS $10.81, revenue ~$3.81B). The key lines: Eylea + Eylea HD combined US net sales (is the HD switch defending the franchise?) and confirmation the Limerick margin drag is resolving as management promised.
Dupixent: global in-market sales and new-indication progress (COPD, expanding label) — the primary growth engine.
Pipeline readouts: factor XI anticoagulant (cardiovascular), oncology bispecifics (Lynozyfic/linvoseltamab and follow-ons), and genetic-medicine collaborations (Alnylam, Intellia) — the optionality that could re-rate the multiple.
Buyback pace: how aggressively the $3.0B authorization is executed at these prices.

Thesis tripwires (what would change the call): Eylea-franchise net sales declining faster than Dupixent-share can offset for two straight quarters; Limerick drag persisting past Q2'26; a major late-stage pipeline failure; or net margin compressing below the mid-20s.

11. Key risks

Eylea erosion (structural — the core risk): biosimilar aflibercept plus Roche's Vabysmo are eroding the legacy franchise; Eylea HD is a defense, not a guarantee. This is the single biggest swing factor and the reason the stock de-rated ~46% from peak.
Dupixent economics are shared: the strongest growth asset is a Sanofi collaboration; Regeneron does not fully control its pricing or trajectory.
Manufacturing/supply: the self-flagged Limerick interruption (REGN-earnings-2026Q2:1463389f1e) shows single-site production risk can dent margins.
US concentration & pricing policy: ~90% of own product revenue is US — exposed to US drug-pricing politics and PBM friction.
Thin external validation: with no high-skill outside analyst in the KB, the bull case rests on our own quant/fundamental read — less corroborated than a high-breadth name.
Pipeline dependence: the re-rating case needs a pipeline win; biotech clinical/regulatory risk is real and binary.

12. Verdict, position sizing & monitoring

Buy — Tactical. Regeneron is a cheap (15× trailing, 12× FY27E), net-cash, 84%-gross-margin biotech that the market has repriced for Eylea decline — and at ~$654 that pessimism looks somewhat overdone given Dupixent's double-digit growth, ~$4B annual FCF, a fresh $3.0B buyback, and a deep pipeline. But the case is quant- and fundamentals-driven, not conviction-driven (only 10 KB claims, one half-weighted management voice), the Eylea overhang is structural, and the technicals are still in a downtrend. That combination is a satellite, not a core.

Sizing: satellite, ~1–3% — a value/optionality position. The overbought +4.7% bounce and death-cross posture argue for scaling in on weakness toward the low-$600s, not chasing.
Monitoring: re-underwrite on the §10 tripwires; formal re-score each earnings print, with Eylea-franchise net sales and Limerick-margin normalization as the two must-watch lines. This verdict is logged as a tracked Synthos call as of 2026-07-03 at $654.27.
Single biggest risk: Eylea structural erosion — the whole value case depends on Dupixent + pipeline offsetting the legacy franchise's decline.

Provenance & disclosures

Traceability: 10 KB claims, breadth 1 (management only), net conviction 0, last claim 2026-04-29 — the two cited claim_ids are real and reconciled inline. This name has no independent high-skill expert coverage in the Synthos KB; the verdict is explicitly quant/fundamentals-driven. Fabricated conviction is structurally impossible (claim-ID reconciliation).
Data as-of: fundamentals 2026-03-31 (Q1'26) · estimates & prices 2026-07-02/03 · expert claims through 2026-04-29. Forward figures are analyst consensus (FMP), labeled as estimates.
Management caveat: REGN_mgmt guidance is management's own book, half-weighted by design.
Not investment advice. Independent research, educational and informational only, never personalized. Hypothetical/forward figures are labeled; the only performance numbers Synthos will headline are the live, real-money Flagship's.
Version: 2026-07-03. Prior versions available via the deep-dive version dropdown ("based on the info at the time").